Abstract:Breast cancer (BC) is the most prevalent neoplasm among women. Genetic and environmental factors lead to BC development and on this basis, several preventive – screening and therapeutic interventions have been developed. Hormones, both in the form of endogenous hormonal signaling or hormonal contraceptives, play an important role in BC pathogenesis and progression. On top of these, breast microbiota includes both species with an immunomodulatory activity enhancing the host's response against cancer cells and species producing proinflammatory cytokines associated with BC development. Identification of novel multitargeted therapeutic agents with poly-pharmacological potential is a dire need to combat advanced and metastatic BC. A growing body of research has emphasized the potential of natural compounds derived from medicinal plants and microbial species as complementary BC treatment regimens, including dietary supplements and probiotics. In particular, extracts from plants such as Artemisia monosperma Delile , Origanum dayi Post , Urtica membranacea Poir. ex Savigny , Krameria lappacea (Dombey) Burdet & B.B. Simpson and metabolites extracted from microbes such as Deinococcus radiodurans and Streptomycetes strains as well as probiotics like Bacillus coagulans and Lactobacillus brevis MK05 have exhibited antitumor effects in the form of antiproliferative and cytotoxic activity, increase in tumors' chemosensitivity, antioxidant activity and modulation of BC – associated molecular pathways. Further, bioactive compounds like 3,3'-diindolylmethane, epigallocatechin gallate, genistein, rutin, resveratrol, lycopene, sulforaphane, silibinin, rosmarinic acid, and shikonin are of special interest for the researchers and clinicians because these natural agents have multimodal action and act via multiple ways in managing the BC and most of these agents are regularly available in our food and fruit diets. Evidence from clinical trials suggests that such products had major potential in enhancing the effectiveness of conventional antitumor agents and decreasing their side effects. We here provide a comprehensive review of the therapeutic effects and mechanistic underpinnings of medicinal plants and microbial metabolites in BC management. The future perspectives on the translation of these findings to the personalized treatment of BC are provided and discussed.

Redefining bioactive small molecules from microbial metabolites as revolutionary anticancer agents

Indispensable role of microbes in anticancer drugs and discovery trends

Marine Cyanobacteria and Microalgae Metabolites—A Rich Source of Potential Anticancer Drugs

Microbial Metabolites-Induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives

Biosynthesis of anticancer phytochemical compounds and their chemistry

In Silico Analysis of Novel Bacterial Metabolites with Anticancer Activities

Phytotherapeutics in Cancer: From Potential Drug Candidates to Clinical Translation

The role of key gut microbial metabolites in the development and treatment of cancer

Endophytic fungi as a potential source of anti-cancer drug

Natural products derived from medicinal plants and microbes might act as a game-changer in breast cancer: a comprehensive review of preclinical and clinical studies

Cure lies in nature: medicinal plants and endophytic fungi in curbing cancer

Unlocking the Therapeutic Potentiality of Natural Products in Cancer Therapy: A Recent Update and Current Prospects

Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies

Plant Metabolomics: The Future of Anticancer Drug Discovery

Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing

Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine

Natural Products/Bioactive Compounds as a Source of Anticancer Drugs

Nature's weapons: Bioactive compounds as anti-cancer agents

Secondary Metabolites from Marine-Derived Fungi and Actinobacteria as Potential Sources of Novel Colorectal Cancer Drugs

An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)

Status and Challenges of Plant-Anticancer Compounds in Cancer Treatment